Xenon Pharmaceuticals Inc.’s Kv7 potassium channel opener XEN-1101 remains very much alive despite the primary endpoint miss in top-line data from the phase II proof-of-concept X-Nova trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback